BOVNF - Enrollment underway in BioInvent/Transgene's BT-001 trial in solid tumors

BioInvent International AB (BOVNF) and Transgene (TRGNF) have enrolled the first patient in a Phase I/IIa clinical trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). The Phase I will be divided into two parts:Part A will enroll up to 36 patients with metastatic/advanced solid tumors and will receive single agent, intra-tumoral administrations of BT-001.Part B will explore the combination of intra-tumoral injections of BT-001 with pembrolizumab in 12 patients with different tumor types.These expansion cohorts will offer the possibility of exploring this approach to treat other malignancies not traditionally addressed with this type of treatment.BT-001 is being co-developed through a 50/50 collaboration between BioInvent and Transgene."BT-001 is a unique oncolytic virus, combining multiple mechanisms-of-action, and has outstanding potential in a wide range of indications thanks to its combination of multiple anti-cancer properties," said Martin Welschof, CEO of BioInvent.

For further details see:

Enrollment underway in BioInvent/Transgene's BT-001 trial in solid tumors